Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials

Table 1 Trial and Baseline Patient Characteristics, and Interventions of RCTs Measuring Cardiovascular Outcomes

	Stable CAD	ACS (91 %) or Acute Stroke (9 %)	Post Successful Elective Balloon PTCA	Post BMS PTCA in DM (31 % ACS)	Symptomatic stable CHF with LVEF ≤ 40 %
Colchicine Dose	0.5 mg/d	1 mg/d	0.5 mg bid	0.5 mg bid	0.5 mg bid
Trial	Nidorf 2013 [14]	Raju 2012 [15]	O’Keefe 1992 [16]	Deftereos 2013 [7]	Deftereos 2014 [17]
Trial	N = 532	N = 80	N = 197	N = 222	N = 267
Trial Characteristics
No. Centres	1	1	1	1	1
Enrolment period	Aug 2008 – May 2010	Apr 2008 – Aug 2009	n/r	n/r	n/r
Treatment/Follow Up	2 (all)/3 (median) yrs	32 days (median)	5.5 months (mean)	6 months (?all)	6 months (all)
Funding	None	Public	n/r	n/r	n/r
Patients	N = 532	N = 80	N = 197	N = 196	N = 279
Mean Age (years)	66	57	60	64	67
% Male	89 %	88 %	86 %	65 %	67 %
BMI				27	26
Diabetes	31 %	16 %	12 %	100 %	17 %
HTN		42 %		49 %	36 %
Smoker	5 %	44 %		38 %
Dyslipidemia		48 %	Total Chol 211 mg/dL		33 %
Prev MI/UA	23 %	18 %
Prev stroke/TIA		4 %
PVD		5 %
CRD	n/r	Excl CrCl <50 mL/min	Excl Cr ≥2.5 mg/dL/ 221 μM	33 % (Excl CrCl <20 mL/min)	Excl eGFR <30 mL/min
Mean LVEF				56 %	28 %
Previous CABG	19 % (Prev PCI 58 %)		26 %
Medications
ASA and/or clopidogrel	93 % (DAPT 12 %)	100 % (DAPT 85 %)
Statin	95 %	98 %			63 %
Beta-Blocker	67 %				79 %
Calcium Channel Blocker	14 %
ACE Inhibitor	58 %				85 % (incl ARB)
Diuretic					69 %

ISSN: 1471-2261